- Healthcare 150
- Posts
- What’s Blocking Healthcare M&A Right Now
What’s Blocking Healthcare M&A Right Now
Healthcare M&A hurdles, regional satisfaction gaps, and wearable tech’s clinical shift.
Good morning, ! Today we’re diving into the main barriers to Healthcare M&A acceleration this year, healthcare satisfaction across different regions and how wearable tech market is entering in its clinical era.
Want to advertise in Healthcare 150? Check out our ad platform, here.
Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.
— The Healthcare150 Team
MICROSURVEY
What’s really holding back healthcare M&A?
According to our proprietary survey of 160 healthcare executives and investors, the market sees three barriers standing in the way of a stronger 2026 deal rebound: regulatory and antitrust scrutiny (37%), valuation gaps between buyers and sellers (32%), and a shortage of scalable, high-quality assets (31%).
The takeaway is notable. Capital availability is no longer the primary constraint. Strategic buyers and PE firms remain active, but execution friction is replacing financing friction. Increased FTC scrutiny and prolonged review timelines continue to slow larger transactions, particularly in provider consolidation and tech-enabled services.
At the same time, valuation expectations remain misaligned. Many sellers are still pricing assets on 2021 growth assumptions, while buyers are underwriting against a slower reimbursement and labor environment.
Perhaps most important, the near parity across all three responses suggests the market lacks a single clearing mechanism. Even if rates fall further in 2026, deal acceleration likely depends more on regulatory clarity and asset quality than on capital costs alone. (More)
HEADLINE OF THE WEEK
Wearables Enter Their Clinical Era
Apple now commands 63% of the wearable market, more than double Fitbit’s 27%, according to Rock Health survey data. Samsung, Garmin, and Oura remain niche by comparison. The implication is becoming harder to ignore: consumer wearables are consolidating into healthcare infrastructure, not just lifestyle hardware.
What matters now is not device adoption. It is data ownership, clinical integration, and reimbursement alignment. As Apple pushes deeper into biometrics, sleep, cardiac monitoring, and AI-enabled health tracking, the competitive battleground shifts from hardware sales to longitudinal patient data and care workflows.
For providers and payers, the opportunity is operational. Wearables could reduce monitoring costs, improve chronic disease management, and expand remote care capacity. For investors, the market is beginning to resemble platform economics more than consumer electronics.
Bottom line: The wearable race is no longer about steps or fitness. It is about who becomes the operating system for continuous healthcare monitoring. (More)
PRESENTED BY EXACT INSIGHT
Imagine turning down Uber at a valuation of $10 million, only to watch it go public at over $80 billion.
That’s exactly what happened to Mark Cuban… a 799,900% return, gone.
But original Shark Tank investor Kevin Harrington built his career doing the opposite: spotting asymmetric opportunities before they go mainstream.
Like Uber turned vehicles into income-generating assets, Mode Mobile is turning smartphones into income streams.
They were named the #1 fastest-growing software company by Deloitte and have already helped their users earn and save over $1B.
Kevin Harrington invested early.
And at just $0.52/share, you can still get in before their potential IPO.
_
Potential Uber return for Marc Cuban does not take into account dilution.
The Deloitte rankings are based on submitted applications and public company database research, with winners selected based on their fiscal-year revenue growth percentage over a three-year period in 2023.
Please read the offering circular at invest.modemobile.com. This is a paid advertisement for Mode Mobile’s Regulation A Offering.
DEAL OF THE WEEK
Deal of the Week: FTC Forces Carve-Outs in Ascension’s $3.9B AmSurg Bet
Ascension’s $3.9B acquisition of AmSurg cleared a major hurdle this week, but only after the FTC forced the nonprofit system to divest seven ambulatory surgery centers across five markets. The message from regulators is clear: outpatient consolidation will face the same scrutiny once reserved for hospitals.
The strategic rationale remains intact. AmSurg adds more than 250 ambulatory surgery centers across 34 states, accelerating Ascension’s pivot away from inpatient-heavy operations toward lower-cost outpatient care. That shift is no longer optional. Health systems are chasing margin stability as reimbursement pressure, labor inflation, and softer inpatient utilization continue to erode hospital economics.
What makes the deal notable is who benefits from the divestitures. Six facilities are going to Optum-owned SCA Health, reinforcing UnitedHealth’s expanding influence across physician services and outpatient infrastructure. Even when regulators intervene, scaled platform players continue gaining share.
The broader implication is structural. Ambulatory surgery is becoming one of healthcare’s most contested battlegrounds, where systems, payers, and PE-backed operators are all racing to control referral flow, procedure volume, and lower-acuity care delivery.
Bottom line: The FTC may have trimmed the edges of the deal, but it did not slow the outpatient land grab. (More)
REGIONAL FOCUS
The Global Health Satisfaction Divide Is Widening
Health system satisfaction is no longer moving in sync globally. North America and East Asia continue to lead perception scores near or above 75%, while Sub Saharan Africa and parts of Latin America remain below 50%, according to Gallup World Poll data. The divergence became even more visible after COVID-19, when higher-income regions recovered faster while emerging markets struggled with workforce shortages, inflation, and uneven healthcare access.
The most notable shift is East Asia’s sharp rebound, climbing above 80% post-pandemic. That suggests aggressive infrastructure investment and digital health expansion are translating into public confidence. Europe, meanwhile, remained remarkably flat near 60%, signaling stability but limited perceived improvement despite elevated spending.
For investors and operators, the implication is structural. Healthcare satisfaction increasingly tracks system adaptability, not just spending levels. Regions modernizing care delivery, digital infrastructure, and access models are pulling ahead, while slower-moving systems face rising political and operational pressure.
Bottom line: Healthcare quality is becoming a competitive regional asset, not just a policy outcome. (More)
"Success is not just about making money. It’s about making a difference."
Unknown